# Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

> **NCT00012376** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Del(5q)
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Blastic Phase Chronic Myelogenous Leukemia
- Chronic Myelomonocytic Leukemia
- Chronic Phase Chronic Myelogenous Leukemia
- Paroxysmal Nocturnal Hemoglobinuria
- Previously Treated Myelodysplastic Syndromes
- Recurrent Adult Acute Myeloid Leukemia
- Refractory Anemia
- Refractory Anemia With Ringed Sideroblasts
- Relapsing Chronic Myelogenous Leukemia
- Thrombocytopenia
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** bryostatin 1
- **BIOLOGICAL:** sargramostim
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00012376
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** 2010-01
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00012376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00012376, "Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00012376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*